A clinical-stage biotech firm leveraging next-generation T-cell engineering to treat severe autoimmune conditions and oncology indications with a focus on scalable manufacturing and regulatory milestones.
Investors may be attracted by the high-value potential of proprietary cell therapy platforms targeting lucrative markets like autoimmune disease and oncology. The company's specialized technology offers a pathway to commercialization with limited direct competition in specific rare disease indications. Strategic partnerships could provide non-dilutive funding and accelerate development timelines, potentially improving the path to profitability.
The lack of current revenue and massive accumulated deficit of $226.6M indicates the company is entirely dependent on future fundraising or a successful product launch to survive. With cash reserves depleted to under $1M and annual operating losses exceeding $10M, the firm faces an imminent liquidity crisis requiring immediate equity dilution. High-risk clinical development stages mean there is no guarantee of regulatory approval or commercial success for its pipeline products.
Brainstorm Cell Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell therapy solutions for autoimmune diseases, cancer, and rare disorders, primarily serving patients in North America and Europe through its proprietary BrainStorm Technology platform.
Despite the absence of revenue, the company reported a net loss of $11.6M in 2024, reflecting continued heavy investment in research and development totaling $4.7M alongside general and administrative costs of $7.0M. Financing activities provided $8.0M in cash flow from operations and financing combined, though other share issuances suggest a net capital raise of $180M over the period to offset the $9.1M cash outflow from operations. The company's cash position remains tight with only $371,000 in ending cash against current liabilities of $9.0M.
The global cell and gene therapy market is experiencing rapid growth driven by advancements in engineering and increasing investment in rare disease treatments. However, the sector remains capital-intensive with long development cycles and high regulatory hurdles that can lead to significant financial losses before any product reaches the market. Competition is intensifying as major pharmaceutical giants enter the space, potentially squeezing margins for smaller clinical-stage biotechs.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $24.8M | $21.4M | $11.7M |
| Operating Income | $-24.8M | $-21.4M | $-11.7M |
| R&D | $14.0M | $10.7M | $4.7M |
| G&A | $10.9M | $10.7M | $7.0M |
| Stock-Based Comp | $1.7M | $1.5M | $750.0K |
| Depreciation | $285.0K | $265.0K | $240.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $545.0K | $4.2M | $70.0K |
| Pre-Tax Income | $-24.3M | $-17.2M | $-11.6M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-24.3M | $-17.2M | $-11.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-24.3M | $-17.2M | $-11.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-24.3M | $-17.2M | $-11.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $3.1M | $1.9M | $385.0K |
| Cash & Equivalents | $772.0K | $1.3M | $187.0K |
| Marketable Securities | $2.2M | — | — |
| Prepaid Expenses | $32.0K | $548.0K | $135.0K |
| Other Current Assets | $91.0K | $51.0K | $63.0K |
| Long-Term Assets | $5.3M | $2.3M | $1.4M |
| PP&E (Net) | $933.0K | $686.0K | $434.0K |
| Operating Leases | $4.4M | $1.4M | $807.0K |
| Other LT Assets | $23.0K | $207.0K | $206.0K |
| Total Assets | $8.5M | $4.2M | $1.8M |
| Current Liabilities | $8.8M | $7.8M | $9.0M |
| Accounts Payable | $6.2M | $5.0M | $6.1M |
| Current Leases | $1.4M | $603.0K | $549.0K |
| Other Current Liab | $1.1M | $1.0M | $1.7M |
| Long-Term Liabilities | $2.7M | $1.3M | $618.0K |
| LT Operating Leases | $2.7M | $672.0K | $171.0K |
| Other LT Liab | $0 | $594.0K | $447.0K |
| Total Liabilities | $11.5M | $9.1M | $9.6M |
| Shareholders' Equity | $-3.0M | $-4.9M | $-7.8M |
| Retained Earnings | $-197.8M | $-215.0M | $-226.6M |
| Total L&E | $8.5M | $4.2M | $1.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-24.3M | $-17.2M | $-11.6M |
| Non-Cash Adjustments | $3.0M | $-3.2M | $1.2M |
| Working Capital Changes | $1.9M | $-21.0K | $1.3M |
| Cash from Operations | $-19.3M | $-20.5M | $-9.1M |
| Capital Expenditures | $29.0K | $18.0K | — |
| Cash from Investing | $998.0K | $2.2M | $12.0K |
| Cash from Financing | $238.0K | $19.0M | $8.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-18.1M | $713.0K | $-1.1M |
| Beginning Cash | $18.9M | $772.0K | $1.5M |
| Ending Cash | $772.0K | $1.5M | $371.0K |
The company's operations are centered around two primary areas: Autoimmune Disease Development, targeting conditions like Rheumatoid Arthritis and Type 1 Diabetes, and Cancer Immunotherapy, focusing on novel T-cell products for oncology. A secondary segment involves Preclinical Research and Technology Licensing, where the firm may collaborate with external partners to advance its proprietary cell engineering platform.
Significant cash burn of $11.6M in 2024 requires substantial external financing, as the company holds minimal cash reserves relative to its operating expenses. The firm currently generates no revenue and has a substantial accumulated deficit, creating high dilution risk for existing shareholders upon equity issuances. Regulatory approval timelines for cell therapies are lengthy and uncertain, delaying potential commercialization milestones. Clinical trial failures or safety concerns could halt development programs entirely.
The company possesses a patented T-cell engineering platform (BrainStorm Technology) designed to enhance cellular potency and manufacturing scalability. Its focus on rare autoimmune diseases offers first-to-market potential in niches with unmet medical needs. The organization maintains strategic partnerships that provide access to specialized patient populations and clinical trial networks without significant upfront capital expenditure.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.